Business Context and Reporting Period
This Form 8-K Current Report was filed by Glucotrack, Inc. (GCTK) on September 9, 2026, covering events occurring on September 4, 2026. The filing details the entry into a Settlement and Release Agreement to resolve disputes regarding indebtedness owed to Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B ("Alto") by Apimeds Pharmaceuticals US, Inc.
Key Financial Metrics and Obligations
The filing outlines specific financial obligations arising from the settlement rather than standard operating metrics. The total settlement value includes:
- Initial Cash Payment: $2.0 million.
- Convertible Promissory Note: $2.0 million principal.
- Legal Fees: Up to $125,000.
- Total Immediate Obligation: Approximately $4.125 million (excluding accrued interest).
Note Terms:
- Interest Rate: 5% per annum.
- Repayment Schedule: Four quarterly installments of $500,000 principal plus interest, from November 30, 2026, to August 31, 2027.
- Conversion Price: $2.98 per share of common stock (subject to adjustments and ownership limitations).
The filing text does not provide clear values for the Company's current revenue, profit, cash flow, margins, or total debt levels outside of this specific settlement.
Material Changes and Dispute Resolution
The primary material change is the resolution of a dispute concerning approximately $10.9 million in indebtedness previously asserted by Alto. The settlement reduces the Company's exposure by establishing a fixed payment structure of $4.0 million in principal plus legal fees, replacing the disputed higher amount. The Company and other settling parties are jointly and severally obligated for these payments.
Outlook, Risks, and Contingencies
Default Risks: If any required payment is not made within the five-business-day cure period, the entire unpaid amount under the Settlement Agreement and Note becomes immediately due and payable. This triggers an increased interest rate and acceleration of obligations.
Equity Dilution: The Note is convertible into common stock at $2.98 per share, subject to a 9.99% beneficial ownership limitation and Nasdaq issuance limits. This creates a potential contingency for future equity dilution.
Release Conditions: Alto's release of claims is contingent upon the full payment of amounts required under the Settlement Agreement and the Note.
Investor Verification Checklist
- Verify the Company's current liquidity position to ensure it can meet the $2.0 million initial payment and subsequent quarterly installments.
- Confirm the exact number of shares issuable upon conversion of the $2.0 million Note at the $2.98 conversion price.
- Review the upcoming Form 10-Q for the full text of the Settlement Agreement and Note to understand specific default triggers and covenants.
- Assess the impact of the joint and several liability on the Company's balance sheet relative to the other settling parties.